Gyre Therapeutics (GYRE) to Release Quarterly Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) is expected to be releasing its earnings data before the market opens on Tuesday, March 25th. Analysts expect Gyre Therapeutics to post earnings of $0.04 per share and revenue of $23.50 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Gyre Therapeutics Stock Performance

Shares of GYRE stock opened at $9.71 on Friday. The business has a fifty day moving average of $11.31 and a 200 day moving average of $12.20. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $19.00.

Wall Street Analysts Forecast Growth

Separately, Noble Financial began coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

Insider Buying and Selling at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 38,054 shares of company stock worth $431,857. Company insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,937 shares of the company’s stock after purchasing an additional 1,996 shares during the quarter. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.